GlaxoSmithKline PakistanKAR:GLAXO +1.58%92 PB Ratio is 3.30 as of Jul. 02, 2026, which is 3% above its 10-year median of 3.20. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.23 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 920 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks worse than 70.65% on this metric.
The historical rank and industry rank for GlaxoSmithKline Pakistan's PB Ratio or its related term are showing as below:
KAR:GLAXO'
s PB Ratio Range Over the Past 10 Years
Min: 1.07 Med: 3.2 Max: 6.22
Current: 3.2
During the past 13 years, GlaxoSmithKline Pakistan's highest PB Ratio was 6.22. The lowest was 1.07. And the median was 3.20.
KAR:GLAXO's PB Ratio is ranked worse than 70.65% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.89
vs KAR:GLAXO: 3.20
During the past 12 months, GlaxoSmithKline Pakistan's average Book Value Per Share Growth Rate was 19.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of GlaxoSmithKline Pakistan was 16.90% per year. The lowest was -4.10% per year. And the median was 6.00% per year.
Back to Basics: PB Ratio
GlaxoSmithKline Pakistan (KAR:GLAXO) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's PB Ratio distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a PB Ratio of 3.30 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GlaxoSmithKline Pakistan and its competitors. This is near median its historical median of 3.20. Over the past decade, GlaxoSmithKline Pakistan's PB Ratio has ranged from 1.07 to 6.22. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #650 out of 920 companies in the Drug Manufacturers industry, placing it in the top 70.7%.
Is GlaxoSmithKline Pakistan's PB Ratio too high?
GlaxoSmithKline Pakistan's current PB Ratio of 3.30 is near median its 10-year median of 3.20. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 6.22. The Drug Manufacturers industry median PB Ratio is 1.89. GlaxoSmithKline Pakistan's value of 3.30 is 74.6% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #650 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #650 out of 920 companies for PB Ratio. This places GlaxoSmithKline Pakistan in the lower half of its industry. The industry median PB Ratio is 1.89. GlaxoSmithKline Pakistan's value of 3.30 is 74.6% above this benchmark. Historically, GlaxoSmithKline Pakistan's own PB Ratio has ranged from 1.07 to 6.22 over the past decade. While the company's 10-year median is 3.20 vs. the industry median of 1.89, GlaxoSmithKline Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.89, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current PB Ratio of 3.30 is 74.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current PB Ratio is 3.30, which is near median its own 10-year median of 3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.23, compared to a current price of ₨376.11 — trading 16% above its estimated fair value. The current PB Ratio is 3.30, which is near median its 10-year median of 3.20 and 74.6% above the Drug Manufacturers industry median of 1.89. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current PB Ratio is 3.30 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨376.11 is trading 16% above its estimated GF Value™ of ₨324.23.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
PB Ratio: 3.30 (near median its 10-year median of 3.20)
GF Value™: ₨324.23 vs. price of ₨376.11 (16% above fair value)
Industry Position: 74.6% above the Drug Manufacturers median (#650 of 920)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
